

# OMEGA-3 PUFA-ENRICHED, LOW-GLYCEMIC-LOAD PLANT-BASED DIET IMPROVES DYSLIPIDEMIA IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA

# Zdzislaw Kochan<sup>1</sup>, Katarzyna Mironiuk<sup>2</sup>, Agnieszka Mickiewicz<sup>3</sup>, Andrzej Karbowski<sup>4</sup>, Ryszard T. Smolenski<sup>5</sup>, Marcin Gruchala<sup>3</sup>, Joanna Karbowska<sup>5</sup>

1 Laboratory of Nutritional Biochemistry, Department of Clinical Nutrition, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland

- 2 Department of Management and Quality Science, Faculty of Management and Quality Science, Gdynia Maritime University, Gdynia, Poland
- 3 1st Department of Cardiology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland
- 4 Research and Academic Computer Network NASK—National Research Institute, Warsaw, Poland
- 5 Department of Biochemistry, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland

### INTRODUCTION

The cumulative LDL-cholesterol (LDL-C) exposure places patients with familial hypercholesterolemia (FH) at high risk for premature atherosclerotic cardiovascular disease (ASCVD) [1]. Extensive evidence supports the cardioprotective effects of omega-3 polyunsaturated fatty acids (PUFA), including their beneficial effects on serum LDL-C levels. AIM

We aimed to evaluate the efficacy of a low-glycemic-load plant-based diet enriched in omega-3 PUFA in reducing blood levels of LDL-C and apolipoprotein B (apoB) in FH patients.

# REFERENCES

1. Chlebus K, Zdrojewski T, Gruchała M, Gałąska R, Pajkowski M, Romanowska-Kocejko M, Chmara M, Pencina MJ. Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country. Am Heart J. 2019; 218: 32–45.

#### CONTACT

zdzislaw.kochan@gumed.edu.pl

# METHODS

Twenty unrelated adult FH patients (12 treated with statins: rosuvastatin, n=10; atorvastatin, n=2) followed a plant-based diet emphasizing the consumption of oily fish, nuts, and vegetable oils rich in omega-3 PUFA for 3-4 months. The experimental diet was individually prescribed for each patient. Serum levels of LDL-C and apoB were measured at baseline and after the intervention using an enzymatic assay and ELISA, respectively. The data from 24-hour dietary recalls, 3-day food records, and food frequency questionnaires (FFQ) were analyzed using the Wilcoxon matched-pairs test or Fisher's exact test.

Assessed for eligibility (n = 69)		Characteristics	Values
$\downarrow \longrightarrow$	Excluded (n = 24) – declined participation	Patients [n]	20
		Gender F/M [n]	14/6
Enrolled (n = 45)		Age	<b>56.3</b> (38-63)
$\downarrow$ $\rightarrow$	Discontinued intervention (n = 18)	BMI	<b>24.8</b> (20.5-32.4)
		Pharmacotherapy (statins)	12
Completed the study (n = 27)		Rosuvastatin/Atorvastatin [n]	10/2
		TC [mg/dl]	<b>260.9</b> (162-364)
$\rightarrow$	Excluded (n = 1) – discontinued statins	LDL-C [mg/dl]	<b>144.8</b> (73-237)
$\rightarrow$	Incomplete data (n = 6) – did not complete post- intervention questionnaires	Mutations:	
		LDLR	7
		APOB	3
Analyzed (n = 20)		LDLR+APOB	1

# RESULTS

During the intervention, the dietary intake of omega-3 PUFA increased (by 249.1%, p=0.00020) but the glycemic load was reduced (by 18.11%, p=0.00073). At the end of the intervention, FH patients showed a reduction in serum LDL-C and apoB levels: LDL-C decreased by 10.49% (p=0.00207) and apoB by 12.51% (p=0.01963).



# CONCLUSIONS

